Cancer Research Journal
2026, Vol. 14, No. 1, pp. 1–5
https://doi.org/10.11648/j.crj.20261401.11

SciencePG
Science Publishing Group

Research Article

Smart Immune-evasive AI Nanobot for Systemic Cancer and Viral Eradication with Regenerative Capabilities (3rd Edition)

Gazy Abdalla Ahmed Ebrahim*

Faculty of Medicine, University of Science and Technology, Khartoum, Sudan

Abstract

This conceptual systems-architecture study presents a foresight-driven blueprint for an artificial intelligence (AI)–powered, immune-evasive nanobot designed for systemic cancer and viral eradication with integrated regenerative capabilities. The proposed platform combines biomimetic immune camouflage, an embedded convolutional neural network (CNN)–based diagnostic core, multimodal nanosensors, stimuli-responsive therapeutic release, regenerative payload deployment, and a theoretical autonomous energy module within a modular nanoscale framework. Unlike conventional nanocarriers that rely primarily on passive targeting mechanisms such as the enhanced permeability and retention (EPR) effect, this system is designed to perform real-time pathological sensing, AI-guided target verification, and adaptive therapeutic activation directly within the in vivo environment. The nanobot architecture integrates validated advances in immune-mimetic membrane cloaking, AI-assisted medical diagnostics, smart nanocarriers, and regenerative biology into a unified theoretical platform. A structured Technology Readiness Level (TRL) assessment and comparative systems analysis are provided to evaluate subsystem maturity and identify translational gaps. While significant technological barriers remain—particularly in nanoscale AI hardware fabrication, in vivo energy harvesting, and micro-integration stability—the model offers an interdisciplinary roadmap toward autonomous and regenerative precision nanomedicine. This study does not present experimental validation but instead proposes a strategic conceptual framework intended to guide future research, engineering development, and ethical regulatory discussions surrounding intelligent therapeutic nanodevices.

Keywords

AI-driven Nanomedicine, Immune-evasive Nanoparticles, Cancer Nanotherapy, Regenerative Nanomedicine, Nanotechnology, Autonomous Therapeutic Systems, Biomimetic Drug Delivery

1. Introduction

The convergence of artificial intelligence (AI) and nanotechnology has opened transformative opportunities in precision medicine. Nanocarriers such as liposomes and polymeric nanoparticles have demonstrated improved targeting and reduced toxicity in cancer therapy [10, 15].

Advances in nanoparticle-based theranostics and smart nanomedicine systems further demonstrate the feasibility of integrating diagnostic and therapeutic functionalities within nanoscale platforms [8, 16].

However, these systems rely largely on passive targeting

*Correspondence: Gazy Abdalla Ahmed Ebrahim (fv81488@gmail.com)

Received: 21 October 2025; **Accepted:** 24 February 2026; **Published:** 5 March 2026

mechanisms such as the enhanced permeability and retention (EPR) effect.

The limitations and variability of the EPR effect in clinical translation have been widely discussed, emphasizing the need for more adaptive targeting strategies [1].

Simultaneously, deep learning models, particularly convolutional neural networks (CNNs), have achieved high diagnostic accuracy in medical imaging and histopathology [6]. Despite these advances, AI systems currently function ex vivo and are not embedded within therapeutic nanosystems.

Recent reviews have emphasized the expanding role of artificial intelligence in biomedical diagnostics and translational medicine, highlighting both its transformative potential and current integration limitations within therapeutic platforms [12, 13, 20].

A major limitation of systemic nanomedicine is rapid immune clearance by the mononuclear phagocyte system (MPS). Strategies such as polyethylene glycol (PEG) coating and biomimetic membrane cloaking have extended circulation time [4, 5], yet these systems remain passive.

This study proposes an integrated, AI-driven, immune-evasive, regenerative nanobot as a next- generation autonomous therapeutic platform.

2. Conceptual Design Framework

2.1. System Overview

The proposed nanobot is conceptually illustrated using a ~10 μm macro-scale schematic representation for architectural clarity. The intended functional implementation, however, is envisioned at the nanoscale through modular nanoengineered subsystems rather than as a single 10 μm physical entity.

1) AI Processing Core
2) Multimodal Sensor Array
3) Therapeutic Payload Module
4) Regenerative Payload Module
5) Immune Camouflage Layer
6) Energy Module
7) Failsafe Mechanisms

2.2. AI Processing Core

An embedded CNN-based processor is envisioned to perform real-time pattern recognition of:

1) Tumor antigens
2) Viral nucleic acids
3) Metabolic stress markers

The AI module would be trained on patient-specific datasets prior to deployment.

2.3. Multimodal Sensor Array

Integrated Nanosensors Detect:

1) Tumor-associated markers
2) Viral RNA fragments
3) pH and oxidative stress variations

The evolution of multifunctional nanomaterials has significantly expanded sensing capabilities in oncologic applications [11].

2.4. Therapeutic Payload Module

A multi-compartment capsule enables controlled release of:

1) Chemotherapeutic agents
2) Antiviral molecules
3) Enzymatic degraders

Release is AI-triggered upon validated pathological detection.

Stimuli-responsive nanocarriers and precision nanoparticle engineering strategies have demonstrated controlled release behavior in complex tumor microenvironments [9, 14].

2.5. Regenerative Payload Module

Contains growth factors (e.g., VEGF, FGF), cytokines (e.g., IL-10), or gene modulators to promote tissue repair [6, 7].

Foundational research in regeneration biology and cellular plasticity supports the theoretical integration of regenerative signaling pathways within advanced therapeutic platforms [2].

2.6. Immune Camouflage Coating

Autologous cell membrane coating mimics “self” markers to evade immune clearance [5].

Biomimetic membrane-functionalized nanoparticles have demonstrated enhanced immune evasion and prolonged systemic circulation in preclinical models [3, 17].

2.7. Energy Module

Theoretical dual system:

1) ATP harvesting nanostructures
2) Micro-hydrogen biofuel cells

2.8. Failsafe Mechanisms

1) AI anomaly detection
2) Self-degradation protocol
3) Optional clinician override

3. Mechanism of Operation

The operational pipeline includes:

1) Systemic Navigation
2) Pathological Detection
3) Target Verification
4) Therapeutic Activation

5) Regeneration Deployment
6) Post-Action Evaluation
7) Mission Termination

4. Methodology

4.1. Study Design

This is a theoretical, foresight-based conceptual study integrating peer-reviewed literature from nanotechnology, AI, immunology, and regenerative medicine.

4.2. Literature Review Strategy

Databases: PubMed, Scopus, IEEE Xplore.

Search terms included "AI in nanomedicine," "immune evasion nanoparticles," and "regenerative nanotherapy."

4.3. System Modeling

A modular design architecture was synthesized based on validated experimental subsystems.

4.4. Limitations

1) No experimental validation
2) No in vivo pharmacokinetic modeling
3) AI hardware miniaturization not yet feasible

5. Technology Readiness Level (TRL) Assessment

Table 1. *Technology Readiness Level Assessment of Nanobot Modules. All TRL levels are estimated based on currently available subsystem maturity and do not represent integrated device readiness.*

Module	TRL	Gap Key
AI Processing Core	2–3	No nanoscale CNN processor
Sensor Array	4	Integration stability
Drug Capsule	5–6	AI-controlled release
Regenerative Module	3–4	Growth regulation control
Immune Camouflage	5–6	Dynamic adaptation

6. Comparative Platform Analysis

Table 2. *Comparison with Existing Nanomedical Systems.*

Feature	Passive	Targeted	Proposed System
Targeting	EPR	Ligand	AI-driven
Immune Evasion	PEG	Partial	Autologous dynamic
Regeneration	None	None	Integrated
Energy	None	None	Autonomous
Decision Making	None	None	Embedded AI

7. Ethical and Regulatory Considerations

Key concerns include:

1) AI autonomy and clinician oversight

Ethical discourse surrounding autonomous medical AI systems underscores the importance of transparency, governance, and risk mitigation in future clinical deployment [19].

2) Informed consent transparency

3) Data security
4) Long-term biocompatibility
5) Equitable access

Future regulatory frameworks must address autonomous therapeutic devices.

8. Challenges and Future Directions

8.1. Technical Challenges

1) Nanoscale AI hardware fabrication

Emerging neuromorphic computing paradigms may provide long-term solutions for energy-efficient edge AI systems suitable for biomedical microdevices [18].

2) Stable in vivo energy harvesting
3) Real-time computation within bloodstream
4) Controlled regenerative signaling

8.2. Biological Challenges

1) Immune variability
2) Biodistribution control
3) Off-target toxicity

8.3. Development Roadmap Phase I: In Silico Modeling

Phase II: Component prototyping
Phase III: Micro-integration
Phase IV: Animal validation
Phase V: Ethical framework
Phase VI: Clinical translation

9. Conclusion

This study proposes a conceptual AI-powered, immune-evasive, regenerative nanobot as a future platform for systemic cancer and viral therapy. While technological barriers remain substantial, the model synthesizes validated advances into a coherent framework for next-generation precision nanomedicine.

The system remains theoretical and has not been experimentally realized. It is presented as a strategic roadmap rather than an immediately deployable technology.

Abbreviations

AI	Artificial Intelligence
CNN	Convolutional Neural Network
EPR	Enhanced Permeability and Retention
MPS	Mononuclear Phagocyte System
TRL	Technology Readiness Level

Author Contributions

Gazy Abdalla Ahmed Ebrahim: Conceptualization, Methodology, Formal Analysis, Investigation, Resources, Visualization, Writing – original draft, Writing – review & editing, Project administration.

Conflicts of Interest

The author declares no conflicts of interest.

References

[1] Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med. 2019; 25(1): 24–29. https://doi.org/10.1038/s41591-018-0316-z

[2] Hu CMJ, Fang RH, Copp J, Luk BT, Zhang L. A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol. 2013; 8(5): 336–340. https://doi.org/10.1038/nnano.2013.54

[3] Parodi A, Quattrocchi N, van de Ven AL, Chiappini C, Evangelopoulos M, Martinez JO, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol. 2013; 8(1): 61–68. https://doi.org/10.1038/nnano.2012.186

[4] Jopling C, Boue S, Izpisua Belmonte JC. Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nat Rev Mol Cell Biol. 2011; 12(2): 79–89. https://doi.org/10.1038/nrm3043

[5] Tanaka EM, Reddien PW. The cellular basis for animal regeneration. Dev Cell. 2011; 21(1): 172–185. https://doi.org/10.1016/j.devcel.2011.06.016

[6] Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018; 2: 719–731. https://doi.org/10.1038/s41551-018-0305-0

[7] Park J, Choi Y, Chang H, Um W, Ryu JH, Kwon IC. Alliance with EPR effect: Combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics. 2017; 7(15): 3905–3918. https://doi.org/10.7150/thno.20885

[8] Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010; 62(11): 1064–1079. https://doi.org/10.1016/j.addr.2010.07.009

[9] Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013; 12(11): 991–1003. https://doi.org/10.1038/nmat3776

[10] Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021; 20(2): 101–124. https://doi.org/10.1038/s41573-020- 00078-2

[11] Cheng H, Shi H, Wang X, Wang Y, Wang J, Wang Y. Recent advances in functional nanomaterials for cancer diagnosis and therapy. Chem Soc Rev. 2020; 49(11): 3269–3304. https://doi.org/10.1039/C9CS00827F

[12] Chen H, Zhang W, Zhu G, Xie J, Chen X. Rethinking cancer nanotheranostics. Nat Rev Mater. 2017; 2: 17024. https://doi.org/10.1038/natrevmats.2017.24

[13] Wang Y, Tang Z. Artificial intelligence in biomedical applications: A review. J Biomed Inform. 2019; 90: 103081. https://doi.org/10.1016/j.jbi.2018.12.012

[14] Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer. 2017; 17(1): 20–37. https://doi.org/10.1038/nrc.2016.108

[15] Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release. 2012; 161(2): 175–187. https://doi.org/10.1016/j.jconrel.2011.09.063

[16] van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019; 14(11): 1007–1017. https://doi.org/10.1038/s41565-019-0567-y

[17] He H, Liu L, Moriguchi S. Neuromorphic computing for AI at the edge: A review. IEEE Trans Neural Netw Learn Syst. 2020; 31(11): 3839–3855. https://doi.org/10.1109/TNNLS.2020.2966415

[18] Xu X, Zhang Y, Li X, Zhang X, Ren X. Cell membrane-coated nanomaterials for cancer immunotherapy. Adv Funct Mater. 2021; 31(13): 2008703. https://doi.org/10.1002/adfm.202008703

[19] Dutta D, Donaldson J. Ethical concerns of AI integration in autonomous medical systems. J Bioeth Inq. 2022; 19(1): 45–56. https://doi.org/10.1007/s11673-021-10103-y

[20] Rusk N. Engineering AI for precision nanomedicine. Nat Methods. 2020; 17(3): 243. https://doi.org/10.1038/s41592-020-0770-3